SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

BioMarin Pharmaceutical Inc. logo
4 weeks ago

Associate Director, Product Communications

BioMarin Pharmaceutical Inc.

San Rafael, CA (Hybrid)Full time$139K/yr – $191K/yr
BioMarin Pharmaceutical Inc. logo
1 month ago

Associate Director, Product Communications, Skeletal Conditions

BioMarin Pharmaceutical Inc.

San Rafael, CA (Hybrid)Full time
BioMarin Pharmaceutical Inc. logo
2 months ago

Associate Director, Skeletal Conditions Business Unit, Product Communications

BioMarin Pharmaceutical Inc.

San Rafael, CA (Hybrid)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
BioMarin Pharmaceutical Inc. logo

Associate Director, Product Communications

BioMarin Pharmaceutical Inc.

San Rafael, CA (Hybrid)

$139K/yr - $191K/yrIn-houseFull-timeSenior level8+ years exp.
4 weeks ago
BioMarin Pharmaceutical Inc. logo

Associate Director, Product Communications, Skeletal Conditions

BioMarin Pharmaceutical Inc.

San Rafael, CA (Hybrid)

In-houseFull-timeMid level8+ years exp.
1 month ago
BioMarin Pharmaceutical Inc. logo

Associate Director, Skeletal Conditions Business Unit, Product Communications

BioMarin Pharmaceutical Inc.

San Rafael, CA (Hybrid)

In-houseFull-timeSenior level8+ years exp.
2 months ago
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.

Associate Director, Product Communications

San Rafael, CA (Hybrid)

$139K/yr – $191K/yrSenior Level8+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the external narrative for BioMarin’s skeletal condition programs, steering media relations, patient storytelling, and executive communications across earned and owned channels.

  • Media strategy and outreach: shape proactive and reactive coverage, manage issues, and coordinate with agencies.
  • Storytelling and content: drive patient/community stories and coordinate press materials and executive messaging across earned, owned, and digital.
  • Cross functional governance: advise on milestones like clinical readouts and congresses, align with digital and corporate communications.

Job Description

Responsibilities

  • Lead integrated communications and PR strategies that position BioMarin as a leader in skeletal conditions, highlighting the innovation and value of its medicines
  • Drive proactive and reactive media engagement and thought leadership to shape external perception and elevate visibility among key stakeholders
  • Identify and amplify compelling patient and community stories that bring the impact of BioMarin’s work to life and drive meaningful media coverage
  • Serve as Corporate Affairs lead on cross-functional teams, providing strategic counsel and supporting key milestones, including clinical data readouts and medical congresses
  • Lead insight-driven campaigns and content development with agency partners, delivering impactful storytelling across earned, owned, and digital channels
  • Oversee press materials and external communications, including press releases, media briefings, and issues management, ensuring alignment and compliance
  • Review media coverage reports, elevating relevant product, competitor, and industry news to key internal stakeholders
  • Partner with Corporate and Digital Communications to amplify messaging across channels, including executive communications, social media, and corporate initiatives

Requirements

  • 8–12 years of experience in public relations, with experience leading product communications in the biopharmaceutical industry, preferably in-house
  • Excellent writer and storyteller with strong verbal communication skills
  • Ability to build consensus and influence across the organization and collaborate effectively within a growing team
  • Experience developing and executing media relations strategies
  • Experience supporting drug product approvals and strong familiarity with the BLA/NDA and sBLA/sNDA process
  • Experience identifying potential issues and leading day-to-day issues management
  • Demonstrated knowledge of regulations governing communications for a publicly traded biopharmaceutical company and solid understanding of the healthcare policy environment
  • BS/BA in science, communications, liberal arts; advanced degree in communications, public relations, journalism, or business preferred

Preferred

    BioMarin Pharmaceutical Inc. logo

    BioMarin Pharmaceutical Inc.

    3.7 Glassdoor

    Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact.Recruitment Fraud Alert Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit.We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.

    Founded in 1997
    San Rafael, California, USA
    3.1K employees (163 in marketing)
    www.BioMarin.com
    68% recommend to a friend
    61% CEO approval

    Traffic Signals

    Monthly Visitors
    116.2K
    Monthly Google Ads Budget
    $130K
    Traffic Source Mix
    Search
    43.9%
    Direct
    36.9%
    Referral
    9%
    Social
    9.5%
    Paid
    0.8%

    Headcount Trend

    Current headcount: ~3.1K

    Marketing Team

    Marketing Team Size
    138 (4% of company)
    Marketing Roles Posted (Last 30 Days)
    3

    Funding

    Total Funding
    $4.2B
    Last Raise
    $3.7B
    Post IPO Debt, 2 months ago

    Funding History

    • Jan 2026
      Post IPO Debt • $3.7B
    • May 2020
      Post IPO Debt • $585.8M

    Recent News

    Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historically - Quarterly Market Summary & Daily Stock Trend Watchlist
    Nov 20, 2025 • newser.com
    How currency fluctuations impact BioMarin Pharmaceutical Inc. stock - July 2025 EndofMonth & Real-Time Sentiment Analysis
    Nov 19, 2025 • newser.com
    How to read the order book for BioMarin Pharmaceutical Inc. - 2025 EndofYear Setup & Low Risk High Reward Ideas
    Nov 14, 2025 • newser.com
    BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
    Nov 11, 2025 • Yahoo Finance
    J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN)
    Nov 4, 2025 • Yahoo Finance
    Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN)
    Oct 31, 2025 • Yahoo Finance
    Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
    Oct 30, 2025 • simplywall.st
    BioMarin Pharmaceutical Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
    Oct 30, 2025 • Yahoo Finance
    FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
    Oct 29, 2025 • PR Newswire
    BioMarin resigned to ending journey with hemophilia A gene therapy Roctavian, seeks divestiture amid sales struggle
    Oct 28, 2025 • Fierce Pharma
    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2025 Earnings Call Transcript
    Oct 28, 2025 • Insider Monkey
    Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy?
    Oct 28, 2025 • Yahoo Finance
    BioMarin Abandons Gene Therapy Roctavian, Cuts Revenue Guidance as Voxzogo Faces Competitors
    Oct 28, 2025 • BioSpace
    BioMarin Pharmaceutical Inc. Reports Third Quarter 2025 Results
    Oct 27, 2025 • TradingView
    BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
    Oct 27, 2025 • PR Newswire
    BioMarin, following sluggish sales, to offload hemophilia gene therapy
    Oct 27, 2025 • BioPharma Dive
    BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings
    Oct 25, 2025 • Yahoo Finance
    Why BioMarin Pharmaceutical Inc. stock is seen as undervalued - Index Update & Risk Controlled Swing Trade Alerts
    Oct 24, 2025 • newser.com
    BioMarin Pharmaceutical Inc expected to post earnings of 37 cents a share - Earnings Preview
    Oct 24, 2025 • TradingView
    BioMarin (NASDAQ: BMRN) sets Q3 2025 financial results call and webcast for 4:30 p.m. ET
    Oct 22, 2025 • Stock Titan
    Can BioMarin Pharmaceutical Inc. stock reach $100 price target - 2025 Buyback Activity & Stepwise Entry and Exit Trade Signals
    Oct 21, 2025 • newser.com
    How strong is BioMarin Pharmaceutical Inc. stock balance sheet - Weekly Risk Summary & Community Verified Trade Signals
    Oct 20, 2025 • newser.com
    How strong is BioMarin Pharmaceutical Inc. stock balance sheet - Portfolio Growth Summary & Accurate Buy Signal Notifications
    Oct 20, 2025 • newser.com
    Activity Recap: Will BioMarin Pharmaceutical Inc. (BM8) stock outperform global peers - Dividend Hike & Verified Entry Point Detection
    Oct 20, 2025 • nchmf.gov.vn
    Using flow based indicators on BioMarin Pharmaceutical Inc. - Weekly Stock Recap & Free Expert Verified Stock Movement Alerts
    Oct 20, 2025 • newser.com
    Is BioMarin Pharmaceutical Inc. stock a safe buy before earnings - IPO Watch & Safe Swing Trade Setup Alerts
    Oct 18, 2025 • nchmf.gov.vn
    Aug Sectors: Why BioMarin Pharmaceutical Inc. stock remains undervalued - July 2025 Levels & AI Forecast Swing Trade Picks
    Oct 18, 2025 • nchmf.gov.vn
    Aug Weekly: How BioMarin Pharmaceutical Inc. stock responds to policy changes - July 2025 PostEarnings & Low Risk Entry Point Guides
    Oct 18, 2025 • nchmf.gov.vn
    Why BioMarin Pharmaceutical Inc. stock remains undervalued - 2025 Big Picture & Reliable Entry Point Trade Alerts
    Oct 18, 2025 • nchmf.gov.vn
    Surprises Report: Why BioMarin Pharmaceutical Inc. stock remains undervalued - 2025 Top Decliners & Comprehensive Market Scan Reports
    Oct 18, 2025 • nchmf.gov.vn
    S P Trends: Is BioMarin Pharmaceutical Inc. (BM8) stock a momentum leader - July 2025 Volume & Consistent Profit Alerts
    Oct 17, 2025 • nchmf.gov.vn
    Aug Reactions: How BioMarin Pharmaceutical Inc. stock responds to policy changes - Market Weekly Review & Comprehensive Market Scan Reports
    Oct 17, 2025 • nchmf.gov.vn
    Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN)
    Oct 17, 2025 • Insider Monkey
    A Look at BioMarin Pharmaceutical’s Valuation as Revenue Growth and Pipeline Optimism Drive Investor Focus
    Oct 15, 2025 • Yahoo Finance
    Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts?
    Oct 8, 2025 • Insider Monkey
    Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
    Oct 6, 2025 • Yahoo Finance
    Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors
    Oct 2, 2025 • Yahoo Finance
    BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low
    Oct 1, 2025 • Insider Monkey
    Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT
    Sep 30, 2025 • Insider Monkey
    BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory
    Sep 16, 2025 • Insider Monkey
    Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M
    Sep 14, 2025 • MedCity News
    Transcript : BioMarin Pharmaceutical Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 11
    Sep 9, 2025 • MarketScreener
    BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
    Sep 8, 2025 • PR Newswire
    BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
    Sep 8, 2025 • BioSpace
    This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
    Sep 8, 2025 • Benzinga.com
    PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
    Sep 8, 2025 • Benzinga.com
    BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
    Sep 6, 2025 • PR Newswire
    BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
    Sep 6, 2025 • MarketScreener
    Biomarin announces positive pivotal phase 3 data for Palynziq® (pegvaliase-pqpz) in adolescents with phenylketonuria at 15th international congress of inborn errors of metabolism
    Sep 6, 2025 • MarketScreener
    Biomarin Announces Positive Pivotal Phase 3 Data For Palynziq® (Pegvaliase-Pqpz) In Adolescents With Phenylketonuria At 15th International Congress Of Inborn Errors Of Metabolism
    Sep 6, 2025 • Reuters
    Sanofi snags BioMarin leader to take on CMO role 8 months after Berger’s exit
    Aug 26, 2025 • FierceBiotech
    NHS cleared to use AZ's Fasenra for rare autoimmune disease
    Aug 14, 2025 • pharmaphorum
    Solid Earnings Reflect BioMarin Pharmaceutical's (NASDAQ:BMRN) Strength As A Business
    Aug 13, 2025 • Yahoo Finance
    Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target
    Aug 12, 2025 • Seattle TechFlash
    BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
    Aug 4, 2025 • PR Newswire
    Enzyme Replacement Therapy Market to Hit USD 21.70 Billion by 2032 | Growing at 8.59% CAGR - SNS Insider
    Aug 4, 2025 • SNS Insider pvt ltd
    BioMarin Announces Appointment of Ian T. Clark to Board of Directors
    Aug 4, 2025 • BioSpace
    BioMarin Announces Appointment of Ian T. Clark to Board of Directors
    Aug 1, 2025 • PR Newswire
    Large And Small-scale Bioprocessing Market Size Expected to Hit USD 248.12 Billion by 2034
    Aug 1, 2025 • BioSpace
    Skeletal Dysplasia Market Growth, Analysis of Key Players, Trends, Drivers
    Jul 30, 2025 • PharmiWeb
    BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
    Jul 23, 2025 • BioSpace
    BioMarin Pharmaceutical Q2 2025 Earnings Call: CEO Alexander Hardy to Present Financial Results
    Jul 22, 2025 • Stock Titan
    Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money
    Jul 16, 2025 • The Motley Fool
    Mucopolysaccharidosis Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook
    Jul 15, 2025 • EIN Presswire
    Red Biotechnology Market Size to Reach USD 1,511.28 Billion by 2034
    Jul 11, 2025 • BioSpace
    Morquio Syndrome Market -Research Report 2025-2035 | Market is Witnessing Early-stage Research Into Gene Therapies
    Jul 10, 2025 • GlobeNewswire News Room
    Skeletal Dysplasia Drugs Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams
    Jul 3, 2025 • EIN Presswire
    BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma
    Jul 1, 2025 • MarketScreener
    Leading Driver In The Lysosomal Enzyme Market 2025: Rising Healthcare Expenditure Fuels Growth In Therapy (ERT) Market
    Jul 1, 2025 • EIN Presswire
    BioMarin Announces Completion of Acquisition of Inozyme
    Jul 1, 2025 • BioSpace
    BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
    Jun 28, 2025 • Yahoo Finance
    Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
    Jun 20, 2025 • Inozyme Pharma Inc.
    Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
    Jun 12, 2025 • Benzinga.com
    Gaucher and Pompe diseases enzyme replacement therapy (ERT) market
    Jun 12, 2025 • PharmiWeb
    The Pharma Letter M&A roundup - May 2025
    Jun 4, 2025 • Pharma Letter
    Next-Generation Achondroplasia Therapies Set to Challenge Voxzogo’s Market Lead | Competitive Intelligence
    Jun 4, 2025 • EIN Presswire
    BioMarin Now Targets $3 Bln Revenue Goal For 2025
    May 30, 2025 • RTTNews
    Phenylketonuria Therapeutic at a Turning Point as Gene Therapy and Small Molecules Challenge Incumbents | CI Insights
    May 30, 2025 • EIN Presswire
    BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease
    May 16, 2025 • MedCity News
    BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
    May 16, 2025 • PR Newswire
    Hereditary Angioedema Global Market Report 2025: Projections And Trends For The Global HAE Industry
    May 14, 2025 • EIN Presswire
    BioMarin presents new data for Voxzogo
    May 12, 2025 • Pharma Letter
    BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential
    May 9, 2025 • Yahoo Finance
    Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025 by Company A-Z, Therapy Focus and Technology Type
    May 9, 2025 • Research and Markets
    Psychedelic Science 2025 Expands Business Track, Announces Select Speakers and Featured Sessions
    May 8, 2025 • Psychedelic Science 2025
    Mucopolysaccharidosis Type I Market to Witness Upsurge in Growth at a CAGR of 8% During the Forecast Period (2025-2034) | DelveInsight
    May 7, 2025 • PR Newswire
    BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
    May 2, 2025 • BioSpace
    Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
    Apr 18, 2025 • Yahoo Finance
    William Blair Issues Pessimistic Outlook for BMRN Earnings
    Apr 18, 2025 • Defense World
    BioMarin Earnings Preview: New CEO Alexander Hardy to Reveal First Quarter Strategy Shift
    Apr 17, 2025 • Stock Titan
    BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
    Apr 17, 2025 • Longview News-Journal
    BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to “Buy” at StockNews.com
    Apr 17, 2025 • Defense World
    BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
    Apr 16, 2025 • Yahoo Finance
    BioMarin Pharmaceutical (BMRN) Expected to Announce Earnings on Wednesday
    Apr 16, 2025 • Defense World
    With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug - San Francisco Business Times
    Apr 15, 2025 • The Business Journals
    Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin
    Apr 15, 2025 • marketscreener.com
    6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
    Apr 11, 2025 • The Motley Fool
    Rare Diseases Treatment Market to Surpass US$36.5 Billion by 2030 Driven by Precision Medicine Breakthroughs | Asia-Pacific Leads in Rare Disease Drug Development with Fast-Tracked Regulatory Reforms
    Apr 8, 2025 • Research and Markets
    Viridian Therapeutics (VRDN) Appoints Jeff Ajer to its Board
    Apr 7, 2025 • StreetInsider.com
    BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
    Apr 3, 2025 • Yahoo Finance